Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly MRI boosts radiation precision for brain cancer patients

NCT ID NCT06108206

Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study tests whether adding weekly MRI scans during radiation treatment can help doctors better target high-grade gliomas, a type of aggressive brain tumor. About 20 adults with newly diagnosed tumors will receive standard radiation plus extra imaging to see if it improves treatment accuracy and predicts where the cancer might return. The goal is to improve disease control and survival without increasing side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Residents of New York or commutable distance for treatment and follow up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma * History and physical examination within 28 days prior to enrollment * Karnofsky performance status 70 or greater * Age 18 years or greater * Negative pregnancy test for females of childbearing potential before 1st research MRI, performed in accordance to institutional guidelines. * Plan to receive standard of care 59.4-60 Gy in 30-33 fractions of radiotherapy. Glioblastoma patients over 65 year-old can receive standard of care hypofractionated radiotherapy including 40 Gy in 15 fractions. Exclusion Criteria: * Prior therapy for tumor except for biopsy or resection, including prior radiotherapy to the brain. * Clinical or radiological evidence of metastatic disease outside the brain * Prior malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic astrocytoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma anaplastic oligodendroglioma astrocytoma (excluding glioblastoma) glioblastoma glioma oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaplastic astrocytoma Anaplastic oligodendroglioma Astrocytoma Glioblastoma

Contacts and locations

Locations

  • Columbia University Irving Medical Center/NYPH

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.